Kyle Bass Gets Diprivan Patent Claims Nixed In PTAB Review
The Patent Trial and Appeal Board on Wednesday invalidated part of a patent covering Fresenius' anesthetic agent Diprivan, capping hedge fund manager Kyle Bass' controversial campaign to target drug patents in...To view the full article, register now.
Already a subscriber? Click here to view full article